产品简要
公司名称 :
安迪生物R&D
产品类型 :
ELISA/assay
产品名称 :
Human VEGFR2/KDR Quantikine ELISA Kit
目录 :
DVR200
规格 :
1 Kit (also 1 Pack (50 Plates), 1 Pack (6 Plates))
价格 :
540美元
更多信息或购买 :
文章摘录数: 34
参考文献
Zarychta E, Rhone P, Bielawski K, Michalska M, Rosc D, Ruszkowska Ciastek B. Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants. Adv Med Sci. 2019;64:216-223 pubmed 出版商
Sánchez Ramírez J, Morera Díaz Y, Bequet Romero M, Hernandez Bernal F, Selman Housein Bernal K, de la Torre Santos A, et al. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants. BMC Immunol. 2017;18:39 pubmed 出版商
Panta S, Yamakuchi M, Shimizu T, Takenouchi K, Oyama Y, Koriyama T, et al. Low grade inflammation inhibits VEGF induced HUVECs migration in p53 dependent manner. Biochem Biophys Res Commun. 2017;483:803-809 pubmed 出版商
Kalender G, Kornberger A, Lisy M, Beiras Fernandez A, Stock U. Kinetics of circulating endothelial progenitor cells in patients undergoing carotid artery surgery. Ther Clin Risk Manag. 2016;12:1841-1847 pubmed 出版商
Salazar R, Capdevila J, Laquente B, Manzano J, Pericay C, Villacampa M, et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer. 2015;15:60 pubmed 出版商
Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla Herttuala S, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer. 2014;14:696 pubmed 出版商
Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, et al. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. Br J Cancer. 2014;110:26-33 pubmed 出版商
Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer. 2013;13:263 pubmed 出版商
Abu El Asrar A, Nawaz M, Kangave D, Mairaj Siddiquei M, Geboes K. Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res. 2013;2013:539658 pubmed 出版商
Jurgensmeier J, Schmoll H, Robertson J, Brooks L, Taboada M, Morgan S, et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer. 2013;108:1316-23 pubmed 出版商
Somlo G, Atzori F, Strauss L, Geese W, Specht J, Gradishar W, et al. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin Cancer Res. 2013;19:1884-93 pubmed 出版商
Widemann B, Kim A, Fox E, Baruchel S, Adamson P, Ingle A, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012;18:6011-22 pubmed 出版商
Hansen T, Andersen C, Nielsen B, Spindler K, Sørensen F, Lindebjerg J, et al. Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. Oncol Lett. 2011;2:1101-1106 pubmed
Sleijfer S, Gorlia T, Lamers C, Burger H, Blay J, Le Cesne A, et al. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br J Cancer. 2012;107:639-45 pubmed 出版商
Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine. 2012;59:442-9 pubmed 出版商
Eskens F, de Jonge M, Bhargava P, Isoe T, Cotreau M, Esteves B, et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res. 2011;17:7156-63 pubmed 出版商
Harmon C, DePrimo S, Raymond E, Cheng A, Boucher E, Douillard J, et al. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med. 2011;9:120 pubmed 出版商
Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F, et al. Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res. 2011;31:2589-95 pubmed
DuBois S, Shusterman S, Ingle A, Ahern C, Reid J, Wu B, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011;17:5113-22 pubmed 出版商
de Groot J, Piao Y, Tran H, Gilbert M, Wu H, Liu J, et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011;17:4872-81 pubmed 出版商
Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer. 2011;104:1262-9 pubmed 出版商
Farace F, Gross Goupil M, Tournay E, Taylor M, Vimond N, Jacques N, et al. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer. 2011;104:1144-50 pubmed 出版商
Konings I, de Jonge M, Burger H, van der Gaast A, van Beijsterveldt L, Winkler H, et al. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br J Cancer. 2010;103:987-92 pubmed 出版商
Hansen T, Sørensen F, Spindler K, Olsen D, Andersen R, Lindebjerg J, et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch. 2010;456:251-60 pubmed 出版商
Wong N, Buckman R, Clemons M, Verma S, Dent S, Trudeau M, et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial . J Clin Oncol. 2010;28:723-30 pubmed 出版商
Hanrahan E, Lin H, Kim E, Yan S, Du D, McKee K, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28:193-201 pubmed 出版商
Guo Q, Carrero J, Yu X, Barany P, Qureshi A, Eriksson M, et al. Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant. 2009;24:3468-73 pubmed 出版商
Zhu A, Sahani D, Duda D, di Tomaso E, Ancukiewicz M, Catalano O, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027-35 pubmed 出版商
Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. Fertil Steril. 2010;94:52-7 pubmed 出版商
Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, et al. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther. 2009;17:278-84 pubmed 出版商
Burstein H, Elias A, Rugo H, Cobleigh M, Wolff A, Eisenberg P, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810-6 pubmed 出版商
Saltz L, Rosen L, Marshall J, Belt R, Hurwitz H, Eckhardt S, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol. 2007;25:4793-9 pubmed
Norden Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res. 2007;13:2643-50 pubmed
Wallner W, Sengenberger R, Strick R, Strissel P, Meurer B, Beckmann M, et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond). 2007;112:51-7 pubmed
产品信息
SKU号 :
DVR200
产品名称 :
Human VEGFR2/KDR Quantikine ELISA Kit
单位尺寸 :
1 Kit (also 1 Pack (50 Plates), 1 Pack (6 Plates))
描述 :
The Human VEGFR2/KDR Quantikine ELISA Kit from R D Systems is a Solid Phase Sandwich ELISA that quantifies human VEGFR2/KDR/Flk-1 in cell culture supernates (100 ul), cell lysates (100 ul), serum (20 ul), edta plasma (20 ul), heparin plasma (20 ul).
靶标 :
VEGFR2 / KDR / Flk-1
类别 :
ELISAs
物种 :
人类
基因符号 :
激酶插入区受体
kit type :
Solid Phase Sandwich ELISA
assay length :
4.5小时
elisaSampleTypes :
Cell Culture Supernates (100 uL), Cell Lysates (100 uL), Serum (20 uL), EDTA Plasma (20 uL), Heparin Plasma (20 uL)
elisaSensitivity :
11.4 pg/mL
elisaRange :
78.10 - 5000 pg/mL
catalog number base :
DVR200
应用 :
酶联免疫吸附测定
2020 Proposedprice USD :
540美元
产品细节 :
The Quantikine Human VEGF R2 Immunoassay is a 4.5 hour solid-phase Immunoassay designed to measure human soluble VEGF R2 in cell culture supernates, cell lysates, serum, and plasma. It contains NS0-expressed recombinant human VEGF R2/Fc Chimera and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human VEGF R2 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human soluble VEGF R2.
别名 :
CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2
储存 :
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
更多信息或购买 :
公司信息
安迪生物R&D
上海市长宁区延安西路726号华敏翰尊国际大厦24A1
info@rndsystemschina.com.cn
http://www.rndsystemschina.com.cn
21 52380373
公司总部: 美国
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.